• Deutsch
Login

Open Access

  • Home
  • Search
  • Browse
  • Publish
  • FAQ

Refine

Author

  • Becker, Sven (1)
  • Bianchini, Giampaolo (1)
  • Del Conte, Gianluca (1)
  • Fasolo, Angelica (1)
  • Gianni, Luca (1)
  • Haibe-Kains, Benjamin (1)
  • Holtrich, Uwe (1)
  • Iwamoto, Takayuki (1)
  • Karn, Thomas (1)
  • Kelly, Catherine M. (1)
+ more

Year of publication

  • 2013 (1)

Document Type

  • Article (1)

Language

  • English (1)

Has Fulltext

  • yes (1)

Is part of the Bibliography

  • no (1)

Institute

  • Medizin (1)

1 search hit

  • 1 to 1
  • 10
  • 20
  • 50
  • 100
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers (2013)
Bianchini, Giampaolo ; Pusztai, Lajos ; Karn, Thomas ; Iwamoto, Takayuki ; Rody, Achim ; Kelly, Catherine M. ; Müller, Volkmar ; Schmidt, Marcus ; Qi, Yuan ; Holtrich, Uwe ; Becker, Sven ; Santarpia, Libero ; Fasolo, Angelica ; Del Conte, Gianluca ; Zambetti, Milvia ; Sotiriou, Christos ; Haibe-Kains, Benjamin ; Symmans, W. Fraser ; Gianni, Luca
Introduction: We examined if a combination of proliferation markers and estrogen receptor (ER) activity could predict early versus late relapses in ER-positive breast cancer and inform the choice and length of adjuvant endocrine therapy. Methods: Baseline affymetrix gene-expression profiles from ER-positive patients who received no systemic therapy (n = 559), adjuvant tamoxifen for 5 years (cohort-1: n = 683, cohort-2: n = 282) and from 58 patients treated with neoadjuvant letrozole for 3 months (gene-expression available at baseline, 14 and 90 days) were analyzed. A proliferation score based on the expression of mitotic kinases (MKS) and an ER-related score (ERS) adopted from Oncotype DX® were calculated. The same analysis was performed using the Genomic Grade Index as proliferation marker and the luminal gene score from the PAM50 classifier as measure of estrogen-related genes. Median values were used to define low and high marker groups and four combinations were created. Relapses were grouped into time cohorts of 0-2.5, 0-5, 5-10 years. Results: In the overall 10 years period, the proportional hazards assumption was violated for several biomarker groups indicating time-dependent effects. In tamoxifen-treated patients Low-MKS/Low-ERS cancers had continuously increasing risk of relapse that was higher after 5 years than Low-MKS/High-ERS cancers [0 to 10 year, HR 3.36; p = 0.013]. High-MKS/High-ERS cancers had low risk of early relapse [0-2.5 years HR 0.13; p = 0.0006], but high risk of late relapse which was higher than in the High-MKS/Low-ERS group [after 5 years HR 3.86; p = 0.007]. The High-MKS/Low-ERS subset had most of the early relapses [0 to 2.5 years, HR 6.53; p < 0.0001] especially in node negative tumors and showed minimal response to neoadjuvant letrozole. These findings were qualitatively confirmed in a smaller independent cohort of tamoxifen-treated patients. Using different biomarkers provided similar results. Conclusions: Early relapses are highest in highly proliferative/low-ERS cancers, in particular in node negative tumors. Relapses occurring after 5 years of adjuvant tamoxifen are highest among the highly-proliferative/high-ERS tumors although their risk of recurrence is modest in the first 5 years on tamoxifen. These tumors could be the best candidates for extended endocrine therapy.
  • 1 to 1

OPUS4 Logo

  • Contact
  • Imprint
  • Sitelinks